Pfizer Inc. (NYSE:PFE) Shares Purchased by Private Advisor Group LLC

Private Advisor Group LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 15.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 849,585 shares of the biopharmaceutical company’s stock after acquiring an additional 113,623 shares during the period. Private Advisor Group LLC’s holdings in Pfizer were worth $24,587,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC acquired a new position in Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the second quarter worth $29,000. Quarry LP acquired a new position in Pfizer during the second quarter worth $31,000. Trivant Custom Portfolio Group LLC lifted its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter worth $34,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.3 %

Pfizer stock opened at $28.85 on Wednesday. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market cap of $163.46 billion, a PE ratio of -62.71, a P/E/G ratio of 1.02 and a beta of 0.67. The stock’s fifty day moving average is $29.07 and its two-hundred day moving average is $28.48.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period last year, the firm earned $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is presently -365.21%.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Thursday, October 3rd. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.